Citations

Clear

511 citation(s) found for "Seth, N".

Associations Between Inflammation and Physical Function in African Americans and European Americans with Prevalent Cardiovascular Risk Factors
Windham, B. Gwen , Wilkening, Steven R., Lirette, Seth T. , Griswold, Michael , Turner, Stephen T. , Kullo, Iftikhar J. , Mosley, Thomas H. , Lirette, Seth

Mayo Clinic

Journal of the American Geriatrics Society | June 16, 2016 | Volume: 64 | Issue: 7 | Pages: 1448-1455

10.1111/jgs.14229 | PMID 27310030 Get It

Objectives To examine associations between inflammation and physical function and potential mediation by white matter hyperintensities ( WMH s) in African Americans ( AA s) and European Americans ( EA s). Design Cross‐sectional analysis using linear and logistic models with generalized estimating equations to account for family clustering, reporting results as regression coefficients (β) and odds ratios ( OR s) adjusted for education, alcohol, exercise, body mass index, hypertension, diabetes mellitus, heart disease, cognition, ankle–brachial index, race (site), and supported interactions. Setting Genetic Epidemiology Network of Arteriopathy‐Genetics of Microangiopathic Brain Injury Study cohort. Participants AA and EA sibships with two or more siblings with hypertension before age 60 (N = 1,960; 65% female, 51% AA , aged 26–91, 50% obese, 72% hypertensive). Measurements Inflammation (C‐reactive protein ( CRP ), interleukin‐6 ( IL 6), soluble tumor necrosis factor receptors ( sTNFR s) 1 and 2, WMH volume (cm 3 ) according to magnetic resonance imaging), walking speed (cm/s) over 25 feet, and mobility difficulty (any self‐reported difficulty walking half a mile). Results In separate models, inflammatory markers were associated with walking speed ( sTNFR 1: β = −2.74, P < .001; sTNFR 2: β = −1.23, P = .03; CRP : β = −1.95, P = .001; IL 6: β = −1.24, P = .03) and mobility difficulty ( sTNFR 1: OR = 1.36, P = .001; sTNFR 2: OR = 1.25, P = .005; CRP : OR = 1.22, P = .005; IL 6: OR = 1.18, P = .02); the association between WMH volume and sTNFR 1 in AA (β = 0.07, P = .06) did not reach typical statistical thresholds. WMH volume was associated with walking speed in AA (β = −3.17, P = .02) but not with mobility difficulty ( OR = 1.10, P = .54). Adjusting for WMH did not change associations. Conclusion In young, middle‐aged, and older adults with prevalent cardiovascular risk factors, multiple inflammatory biomarkers were associated with slower walking speed independent of microvascular disease in the brain. There was little evidence of mediation by brain WMH volume. Inflammation may contribute to physical function impairments through pathways other than brain microvascular disease, particularly in AA s.
Monosialoganglioside‐Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins
Truran, Seth , Weissig, Volkmar , Guzman‐Villanueva, Diana, Karamanova, Nina , Senapati, Subhadip , Burciu, Camelia , Ramı́rez-Alvarado, Marina , Blancas‐Mejía, Luis M. , Lindsay, Stuart , Hari, Parameswaran , Migrino, Raymond Q. , Ramirez-Alvarado, Marina, Blancas-Mejia, Luis M, Franco, Daniel , Ramirez-Alvarado, Marina , Hari, Parameswaran

Mayo Clinic

Journal of the American Heart Association | June 14, 2016 | Volume: 5 | Issue: 6 | Pages: No page available

10.1161/jaha.116.003318 | PMID 27412900 Get It

Background Light chain amyloidosis (AL) is associated with high mortality, especially in patients with advanced cardiovascular involvement. It is caused by toxicity of misfolded light chain proteins ( LC ) in vascular, cardiac, and other tissues. There is no treatment to reverse LC tissue toxicity. We tested the hypothesis that nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (GM1 ganglioside–containing nanoliposomes [ NLGM 1]) can protect against LC ‐induced human microvascular dysfunction and assess mechanisms behind the protective effect. Methods and Results The dilator responses of ex vivo abdominal adipose arterioles from human participants without AL to acetylcholine and papaverine were measured before and after exposure to LC (20 μg/mL) with or without NLGM 1 (1:10 ratio for LC : NLGM 1 mass). Human umbilical vein endothelial cells were exposed for 18 to 20 hours to vehicle, LC with or without NLGM 1, or NLGM 1 and compared for oxidative and nitrative stress response and cellular viability. LC impaired arteriole dilator response to acetylcholine, which was restored by co‐treatment with NLGM 1. LC decreased endothelial cell nitric oxide production and cell viability while increasing superoxide and peroxynitrite; these adverse effects were reversed by NLGM 1. NLGM 1 increased endothelial cell protein expression of antioxidant enzymes heme oxygenase 1 and NAD (P)H quinone dehydrogenase 1 and increased nuclear factor, erythroid 2 like 2 (Nrf‐2) protein. Nrf‐2 gene knockdown reduced antioxidant stress response and reversed the protective effects of NLGM 1. Conclusions NLGM1 protects against LC ‐induced human microvascular endothelial dysfunction through increased nitric oxide bioavailability and reduced oxidative and nitrative stress mediated by Nrf‐2–dependent antioxidant stress response. These findings point to a potential novel therapeutic approach for light chain amyloidosis.
10 Electrocardiographic predictors of torsadogenic risk during dofetilide or sotalol initiation: utility of a novel T wave analysis programme
Sugrue, Alan , Křemen, Václav , Qiang, Bo , Friedman, Paul A. , Ackerman, Michael J. , Sheldon, Seth H. , DeSimone, Christopher V. , Asirvatham, Samuel J. , Noseworthy, Peter A. , Kremen, Vaclav

Mayo Clinic

Moderated Poster Abstracts 1 | June 8, 2016 | Volume: No volume available | Issue: No issue available | Pages: A5.2-A5

10.1136/heartjnl-2015-308621.10 Get It

Multimodality Imaging of Foreign Bodies in and Around the Heart
Illman, Jeffery E., Maleszewski, Joseph J. , Byrne, Suzanne , Kligerman, Seth , Foley, Thomas A. , Young, Phillip M. , Bois, John P. , Malik, Neera, Araoz, Philip A. , Byrne, Suzanne C, Gotway, Michael B. , Morris, Jonathan M.

Mayo Clinic

Future Cardiology | May 3, 2016 | Volume: 12 | Issue: 3 | Pages: 351-371

10.2217/fca-2015-0010 | PMID 27139781 Get It

Clinical Predictors of a Diagnosis of Common Variable Immunodeficiency-related Granulomatous-Lymphocytic Interstitial Lung Disease
Mannina, Amar, Swigris, Jeffrey J. , Solomon, Joshua J. , Huie, Tristan J. , Yunt, Zulma X., Truong, Tho Q., Brown, Kevin K. , Achcar, Rosane Duarte , Olson, Amy L. , Cox, Christian W. , Kligerman, Seth , Pérez, Evans R. Fernández , Chung, Jonathan Hero , Curran‐Everett, Douglas

Mayo Clinic

Annals of the American Thoracic Society | April 11, 2016 | Volume: 13 | Issue: 7 | Pages: 1042-1049

10.1513/annalsats.201511-728oc | PMID 27064856 Get It

Abstract Rationale Granulomatous-lymphocytic interstitial lung disease (GLILD) has emerged as a major cause of morbidity in patients with common variable immunodeficiency (CVID). While GLILD is among the most serious noninfectious pulmonary complications of CVID, risk factors for this condition have not been reported. Objectives To identify clinical, physiologic, and serologic risk factors for GLILD in adults with CVID. Methods Of 345 consecutive adult patients with CVID, we identified 34 in the National Jewish Health research database who had a radiographic-pathologic diagnosis of GLILD evaluated between 2002 and 2014. Each case was age and sex matched to 52 CVID control subjects. We used logistic regression to determine independent predictors of GLILD. A mixed effects model was used to estimate the longitudinal change in percent predicted FVC. Measurements and Main Results: The mean time from CVID diagnosis to GLILD detection was 7.8 years. Compared with matched control subjects, cases were more likely to have a history of autoimmune cytopenia, hypersplenism, polyarthritis, lower marginal zone and switched memory B cells, and restrictive lung function. Multivariate analysis revealed that hypersplenism (odds ratio [OR], 24; 95% confidence interval [CI], 4.5–179.1), polyarthritis (OR, 19; 95% CI, 2.3–206.8), and percent predicted FVC (OR, 0.93; 95% CI, 0.87–0.98) were independently associated with the development of GLILD. The rate of change of percent predicted FVC (slope, P = 0.48) did not vary significantly in patients with GLILD over a mean follow-up of 7 years after diagnosis. Conclusions Hypersplenism and polyarthritis are strong risk factors for GLILD in patients with CVID. Percent predicted FVC remained stable over time in patients with GLILD.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, McAlindon, Timothy E. , Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis Care & Research | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-25

10.1002/acr.22783 | PMID 26545825 Get It

ObjectiveTo develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA).MethodsWe conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.ResultsThe guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.ConclusionThis RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, Jasvinder A. , Bridges, S. Louis , Bannuru, Raveendhara R. , Sullivan, Matthew C. , Vaysbrot, Elizaveta E., McNaughton, Christine, Osani, Mikala C. , Parks, Deborah, Kavanaugh, Arthur, O’Dell, James R., Leong, Amye , Matteson, Eric L. , Drevlow, Barbara E., Ginsberg, Seth, Grober, James, Clair, E. William St. , Tindall, Elizabeth A., Miller, Amy S., McAlindon, Timothy E. , Saag, Kenneth G. , Akl, Elie A. , Shmerling, Robert H. , Curtis, Jeffrey R. , Furst, Daniel E. , King, Charles M. , Schousboe, John T. , Grober, James, Singh, Jasvinder A , Bannuru, Raveendhara R

Mayo Clinic

Arthritis & Rheumatology | November 6, 2015 | Volume: 68 | Issue: 1 | Pages: 1-26

10.1002/art.39480 | PMID 26545940 Get It

Objective To develop a new evidence‐based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease‐modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat‐to‐target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision‐making process taking into account patients’ values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
Expression and function of the Scn5a‐encoded voltage‐gated sodium channel NaV1.5 in the rat jejunum
Mazzone, Amelia , Strege, Peter R. , Saravanaperumal, Siva Arumugam , Sha, L., Higgins, Shauna , Eisenman, Seth T., Bernard, C, Geurts, Aron M. , Kline, Crystal F., Mohler, Peter J. , Farrugia, Gianrico , Sha, Lei , Beyder, Arthur , Gibbons, Simon J. , Sha, L., Higgins, S., Strege, Peter R , Mazzone, Amelia

Mayo Clinic

Neurogastroenterology & Motility | October 13, 2015 | Volume: 28 | Issue: 1 | Pages: 64-73

10.1111/nmo.12697 | PMID 26459913 Get It

AbstractBackgroundThe SCN5A‐encoded voltage‐gated sodium channel NaV1.5 is expressed in human jejunum and colon. Mutations in NaV1.5 are associated with gastrointestinal motility disorders. The rat gastrointestinal tract expresses voltage‐gated sodium channels, but their molecular identity and role in rat gastrointestinal electrophysiology are unknown.MethodsThe presence and distribution of Scn5a‐encoded NaV1.5 was examined by PCR, Western blotting and immunohistochemistry in rat jejunum. Freshly dissociated smooth muscle cells were examined by whole cell electrophysiology. Zinc finger nuclease was used to target Scn5a in rats. Lentiviral‐mediated transduction with shRNA was used to target Scn5a in rat jejunum smooth muscle organotypic cultures. Organotypic cultures were examined by sharp electrode electrophysiology and RT‐PCR.Key ResultsWe found NaV1.5 in rat jejunum and colon smooth muscle by Western blot. Immunohistochemistry using two other antibodies of different portions of NaV1.5 revealed the presence of the ion channel in rat jejunum. Whole cell voltage‐clamp in dissociated smooth muscle cells from rat jejunum showed fast activating and inactivating voltage‐dependent inward current that was eliminated by Na+ replacement by NMDG+. Constitutive rat Scn5a knockout resulted in death in utero. NaV1.5 shRNA delivered by lentivirus into rat jejunum smooth muscle organotypic culture resulted in 57% loss of Scn5a mRNA and several significant changes in slow waves, namely 40% decrease in peak amplitude, 30% decrease in half‐width, and 7 mV hyperpolarization of the membrane potential at peak amplitude.Conclusions & InferencesScn5a‐encoded NaV1.5 is expressed in rat gastrointestinal smooth muscle and it contributes to smooth muscle electrophysiology.
HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer
Roy, Debarshi , Camacho-Pereira, Juliana , Khurana, Ashwani, Chini, Eduardo N. , Yang, Lifeng , Baddour, Joelle, Stilles, Katherine, Padmabandu, Seth, Leung, Sam, Lowe, Val J. , Dierks, Thomas , Hammond, Edward , Dredge, Keith , Nagrath, Deepak , Shridhar, Viji , Mondal, Susmita, Chini, Eduardo, Mondal, Susmita , Kalloger, Steve E. , Gilks, C. Blake

Mayo Clinic

Oncotarget | September 29, 2015 | Volume: 6 | Issue: 32 | Pages: 33705-33719

10.18632/oncotarget.5605 | PMID 26378042 Get It

Pseudoachalasia secondary to bariatric surgery
Sweetser, Seth , Katzka, David A. , Ravi, Karthik

Mayo Clinic

Diseases of the Esophagus | September 10, 2015 | Volume: 29 | Issue: 8 | Pages: 992-995

10.1111/dote.12422 | PMID 26354386 Get It